🇺🇸 FDA
Patent

US 11045472

Quinazoline-pyridine derivatives for the treatment of cancer-related disorders

granted A61KA61K31/4709A61K31/517

Quick answer

US patent 11045472 (Quinazoline-pyridine derivatives for the treatment of cancer-related disorders) held by Arcus Biosciences, Inc. expires Mon Jun 24 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Arcus Biosciences, Inc.
Grant date
Tue Jun 29 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 24 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/4709, A61K31/517, A61K31/704, A61K33/243